Longliv Ventures, the consumer digital health fund, has announced the completion of a US $10 million strategic investment in Sight Diagnostics, a cutting-edge company that’s transforming point-of-care diagnostics.
Based in Tel Aviv, Israel, Sight Diagnostics provides patients with affordable, lab-grade complete blood count (CBC) test results in minutes rather than days by combining advanced image processing with artificial intelligence, analyzing blood samples taken by finger prick rather than by venous blood.
Established in 2018, Longliv Ventures focuses on investments in early stage ventures that seek to address significant health and wellness issues capable of producing global impact. Longliv Ventures is a member of CK Hutchison Holdings Group (CKHH).
Longliv Ventures led the Sight Diagnostics round of a total of $27.8 million in Series C funding. Other participants in the round include Jack Nicklaus II, a healthcare philanthropist and board member of the Nicklaus Children’s Health Care Foundation, Steven Esrick, a healthcare impact investor, and an additional major medical equipment manufacturer, as well as existing investors OurCrowd, Go Capital, and New Alliance Capital.
Yossi Pollak, CEO of Sigh Diagnostics
The company will use the funding first and foremost to ramp up the global expansion of OLO, Sight's lab-grade point-of-care blood diagnostics system, and with Longliv Ventures as a strategic investor we look forward to an effective and rapid expansion of our sales.
David Gordon, Head of Investments of Longliv Ventures
We believe Sight Diagnostics is set to revolutionize medical processes in many types of clinical settings, as well as to give rise to new services at retail points of care.
